Stereotaxis reported its financial results for the fourth quarter and full year ended December 31, 2024, on March 3, 2025. Fourth-quarter revenue totaled $6.3 million, a 39% increase compared to $4.6 million in the prior year's fourth quarter. Full-year 2024 revenue reached $26.9 million, comparable to $26.8 million in 2023.
The fourth-quarter revenue growth was driven by $1.4 million in system revenue from Genesis systems and $4.9 million in recurring revenue, benefiting from a full quarter's contribution from the Access Point Technologies acquisition. The company reported a positive free cash flow of $1.3 million for the fourth quarter, ending the year with $12.4 million in cash and no debt.
For the full year 2025, Stereotaxis anticipates double-digit revenue growth. Recurring revenue is projected to scale from $5 million in the first quarter to $7 million in the fourth quarter, driven by an expanded portfolio of catheters. System revenue is expected to remain approximately flat at $2-3 million per quarter, with modest contributions from GenesisX in Europe and Genesis in China. The company expects reduced cash use in 2025 compared to 2024, supporting its product ecosystem and commercialization efforts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.